Merck Gains Positive EU CHMP Opinion for KEYTRUDA and Padcev
RAHWAY, N.J. — September 18, 2026 Merck announced that the European Medicines Agency’s Committee for Medicinal Products for Human...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
RAHWAY, N.J. — September 18, 2026 Merck announced that the European Medicines Agency’s Committee for Medicinal Products for Human...
